CYP7A1 and cerebrotendinous xanthomatosis: The authorization for indications sterol 27-hydroxylase (cerebrotendinous xanthomatosis, CTX), α-methylacyl-CoA racemase (AMACR) deficiency and cholesterol 7α-hydroxylase (CYP7A1) deficiency was withdrawn in 2020 at the request of the marketing authorization holder due to commercial reasons [16].